A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis (Q40327635)
Jump to navigation
Jump to search
scientific article published on 17 February 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis |
scientific article published on 17 February 2017 |
Statements
1 reference
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis (English)
1 reference
Gerd R Burmester
1 reference
Eduardo Mysler
1 reference
Mariusz Korkosz
1 reference
Iain B McInnes
1 reference
Joel Kremer
1 reference
Pedro Miranda
1 reference
Andrea Rubbert-Roth
1 reference
Matthew A Sleeman
1 reference
Alex Godwood
1 reference
Dominic Sinibaldi
1 reference
Xiang Guo
1 reference
Wendy I White
1 reference
Bing Wang
1 reference
Chi-Yuan Wu
1 reference
Patricia C Ryan
1 reference
David Close
1 reference
Michael E Weinblatt
1 reference
EARTH EXPLORER 1 study investigators
1 reference
17 February 2017
1 reference
1 reference
1020-1030
1 reference
Identifiers
1 reference